Literature DB >> 14652649

Increased neutrophil mediator release in patients with pulmonary hypertension--suppression by inhaled iloprost.

Frank Rose1, Katja Hattar, Sybille Gakisch, Friedrich Grimminger, Horst Olschewski, Werner Seeger, Annette Tschuschner, Ralph T Schermuly, Norbert Weissmann, Jörg Hanze, Ulf Sibelius, Hossein A Ghofrani.   

Abstract

Polymorphonuclear neutrophils (PMN) have been implicated in various vascular inflammatory processes. We isolated PMN from venous blood samples of 10 patients with severe primary pulmonary arterial hypertension (PPH), 7 patients with pulmonary hypertension secondary to chronic thromboembolism (CTEPH), and 12 healthy controls. When stimulated with the calcium-ionophore A23187, platelet activating factor (PAF) or the microbial agent n-formyl-Methionyl-Leucyl-Phenylalanine (fMLP), significantly increased release of elastase and superoxide anion was noted in both groups with pulmonary hypertension. Moreover, the neutrophils of CTEPH patients responded with an enhanced liberation of leukotriene (LT) B(4) and 5-hydroxyeicosatetraenoic acid (5-HETE). Inhalation of aerosolized iloprost (5 microg) caused a rapid decline in pulmonary vascular resistance, in both PPH and CTEPH. This hemodynamic response was paralleled by a significant suppression of ionophore- and ligand-induced elastase and superoxide release, as well as LTB(4) and 5-HETE formation. The neutrophil inhibitory effect of the inhalation maneuver was fully reproduced by in vitro incubation of neutrophils with 1-10 pg/ml iloprost for 2 hours. This is the first study to demonstrate that circulating neutrophils from patients with PPH and CTEPH possess an enhanced readiness to respond with inflammatory mediator generation to different stimulatory agents ex-vivo, and that PMN respiratory burst, elastase secretion and leukotriene generation are promptly reduced by an iloprost inhalation maneuver. Neutrophils might participate in the inflammatory processes in pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14652649     DOI: 10.1160/TH03-03-0173

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function.

Authors:  Marco Idzko; Hamida Hammad; Menno van Nimwegen; Mirjam Kool; Nanda Vos; Henk C Hoogsteden; Bart N Lambrecht
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

3.  Increased Antielastase Activity in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Jingxu Guo; Katharine Lodge; Michael Newnham; Katherine Bunclark; Mark Toshner; Nicholas W Morrell; Wei Li
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

Review 4.  The use of inhaled prostaglandins in patients with ARDS: a systematic review and meta-analysis.

Authors:  Brian M Fuller; Nicholas M Mohr; Lee Skrupky; Susan Fowler; Marin H Kollef; Christopher R Carpenter
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

5.  Umbilical cord blood metabolomics reveal distinct signatures of dyslipidemia prior to bronchopulmonary dysplasia and pulmonary hypertension.

Authors:  Michael R La Frano; Johannes F Fahrmann; Dmitry Grapov; Theresa L Pedersen; John W Newman; Oliver Fiehn; Mark A Underwood; Karen Mestan; Robin H Steinhorn; Stephen Wedgwood
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-08-16       Impact factor: 5.464

6.  Interleukin 13- and interleukin 17A-induced pulmonary hypertension phenotype due to inhalation of antigen and fine particles from air pollution.

Authors:  Sung-Hyun Park; Wen-Chi Chen; Nafiseh Esmaeil; Benjamin Lucas; Leigh M Marsh; Joan Reibman; Gabriele Grunig
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

Review 7.  Nets, pulmonary arterial hypertension, and thrombo-inflammation.

Authors:  Luís Pedro Baptista de Barros Ribeiro Dourado; Mário Santos; Daniel Moreira-Gonçalves
Journal:  J Mol Med (Berl)       Date:  2022-04-20       Impact factor: 4.599

8.  Plasma Cell-Free DNA Predicts Survival and Maps Specific Sources of Injury in Pulmonary Arterial Hypertension.

Authors:  Sean Agbor-Enoh; Michael A Solomon; Samuel B Brusca; Jason M Elinoff; Yvette Zou; Moon Kyoo Jang; Hyesik Kong; Cumhur Y Demirkale; Junfeng Sun; Fayaz Seifuddin; Mehdi Pirooznia; Hannah A Valantine; Carl Tanba; Abhishek Chaturvedi; Grace M Graninger; Bonnie Harper; Li-Yuan Chen; Justine Cole; Manreet Kanwar; Raymond L Benza; Ioana R Preston
Journal:  Circulation       Date:  2022-08-25       Impact factor: 39.918

9.  Neutrophil Extracellular Traps in Atherosclerosis and Thrombosis.

Authors:  Thomas M Hofbauer; Anna S Ondracek; Irene M Lang
Journal:  Handb Exp Pharmacol       Date:  2022

10.  Exploratory analysis of the neutrophil to lymphocyte ratio in patients with pulmonary arterial hypertension.

Authors:  Lars Harbaum; Kaaja M Baaske; Marcel Simon; Tim Oqueka; Christoph Sinning; Antonia Glatzel; Nicole Lüneburg; Karsten Sydow; Carsten Bokemeyer; Hans Klose
Journal:  BMC Pulm Med       Date:  2017-04-26       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.